Regulatory T-cell therapy is a safe and well-tolerated potential approach for treating refractory Crohn's disease

Nature Reviews Gastroenterology and Hepatology

Volumn 9, Issue 10, 2012, Pages 559-

  McLarnon, Andy ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FOOD ANTIGEN; OVALBUMIN;

ANTIGEN SPECIFICITY; CELL ISOLATION; CROHN DISEASE; DISEASE ACTIVITY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IN VITRO STUDY; LYMPHOCYTE CULTURE; LYMPHOCYTE TRANSFER; MORTALITY; MULTICENTER STUDY (TOPIC); NOTE; OPEN STUDY; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REMISSION; TREATMENT OUTCOME;

EID: 84867226957     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2012.167     Document Type: Note

References (1)

1. Desreumaux, P. et al. Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. Gastroenterology doi:10.1053/j.gastro.2012.07.116